Clinical Trials Logo

Clinical Trial Summary

The goal of this research is to test if the conditioning regimen, fludarabine and total body irradiation (FluTBI), can lead to a safer and more effective stem cell transplant treatment regimen for ALL patients older than 40 years of age and/or younger patients with high risk medical conditions. The primary objective is to establish the efficacy of allo HCT in older ALL patients using myeloablative FluTBI conditioning regimen. The investigators are also assessing the safety and toxicity of allo HCT in older ALL patients using myeloablative FluTBI conditioning regimen.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01991457
Study type Interventional
Source University of Alabama at Birmingham
Contact
Status Completed
Phase Phase 2
Start date August 27, 2013
Completion date August 23, 2022

See also
  Status Clinical Trial Phase
Completed NCT01239875 - Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma Early Phase 1
Active, not recruiting NCT02396134 - Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Phase 2
Terminated NCT02043587 - Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Phase 2
Completed NCT01484015 - Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Phase 1
Recruiting NCT03564704 - Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Phase 2/Phase 3